Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Core Viewpoint - Corvus Pharmaceuticals, Inc. will host a conference call and webcast on March 25, 2025, to provide a business update and report its fourth quarter and full year 2024 financial results [1]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel approach to immunotherapy for various cancer and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is also developing other clinical-stage candidates targeting a range of cancer indications [3]. Conference Call Details - The conference call can be accessed by dialing 1-800-717-1738 for domestic calls or 1-646-307-1865 for international calls, or through a provided link for instant access [2]. - A live webcast will be available via the investor relations section of the Corvus website, with a replay accessible for 90 days [2].